Nicara Corteza Caston - Brightlocal News
Vyndamax ® (tafamidis) is an oral therapy developed by pfizer that is indicated for the treatment of cardiomyopathy in adults with wild-type or hereditary transthyretin amyloidosis (hattr) to reduce … Transthyretin amyloid cardiomyopathy (attr-cm) is a type of amyloidosis, which is a group of diseases where abnormal proteins (amyloids) build up and affect areas of the body. The hereditary forms of amyloidosis are autosomal dominant diseases characterized by deposition of variant proteins, in dis-tinctive tissues.
Attr-cm, or transthyretin cardiac amyloidosis, is a heart condition that often goes unnoticed and gets worse over time attr-cm happens when a protein called transthyretin (ttr) breaks down and … Vyndamax is a prescription medicine used to treat adults with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (attr-cm) to reduce death and hospitalization … Fda-approved indication1 vyndaqel and vyndamax are transthyretin stabilizers indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (attr … See safety & benefits of vyndamax®, an rx treatment for transthyretin amyloid cardiomyopathy (attr-cm), and read about the moa and disease impact.
